PARP1 and pachyonychia congenita: The MEK inhibitor U0126 shows different effects on the level of autophagy and PARP-1 degradation in response to GEM between KLM1 and KLM1-R cells, indicating that possibly limitations exist on the therapeutic strategy for targeting the EGFR/Ras/ERK pathway in PC.